Prolonged viral shedding and antibody persistence in patients with COVID-19

SARS-CoV-2 as a new global threat has affected global population for one year. Despite the great effort to eradicate this infection, there are still some challenges including different viral presentation, temporal immunity in infected individuals and variable data of viral shedding. We studied 255 C...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Microbes and infection 2021-05, Vol.23 (4-5), p.104810-104810, Article 104810
Hauptverfasser: Fotouhi, Fatemeh, Salehi-Vaziri, Mostafa, Farahmand, Behrokh, Mostafavi, Ehsan, Pouriayevali, Mohammad Hassan, Jalali, Tahmineh, Mazaheri, Vahideh, Sadat Larijani, Mona, Tavakoli, Mahsa, Eshratkhah mohammadnejad, Azita, Afzali, Neda, Zokaei, Afsaneh, Hosseini, SeyedeAtefe, Mortazavipour, Mohamad Mahdi, Oskouei, FaridehNiknam, Ramezani, Amitis
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:SARS-CoV-2 as a new global threat has affected global population for one year. Despite the great effort to eradicate this infection, there are still some challenges including different viral presentation, temporal immunity in infected individuals and variable data of viral shedding. We studied 255 COVID-19 suspected individuals to assess the viral shedding duration and also the antibody development against SARS-CoV-2 among the cases. Real Time RT-PCR assay was applied to determine the virus presence and SARS-CoV-2 antibodies were evaluated using SARS-CoV-2 IgM and IgG kits. 113 patients were confirmed for COVID-19 infection. The patients were followed until negative PCR achieved. The median viral shedding among studied population was obtained 34.16 (±17.65) days which was not significantly associated with age, sex and underlying diseases. Shiver and body pain were found in prolonged form of the infection and also patients who had gastrointestinal problems experienced longer viral shedding. Moreover, IgG was present in 84% of patients after 150 days. According to this data, the median viral shedding prolongation was 34.16 days which indicates that 14 days isolation might not be enough for population. In addition, IgG profiling indicated that it is persistent in a majority of patients for nearly 6 months which has brought some hopes in vaccine efficacy and application.
ISSN:1286-4579
1769-714X
DOI:10.1016/j.micinf.2021.104810